



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 09/674,913 | 05/25/2001 | Gustav Gaudernack | 1702.401600 | 7022 |

5514 7590 09/18/2002

FITZPATRICK CELLA HARPER & SCINTO
30 ROCKEFELLER PLAZA
NEW YORK, NY 10112

EXAMINER

NICHOLS, CHRISTOPHER J

| ART UNIT | PAPER NUMBER |
|----------|--------------|
|----------|--------------|

1647

DATE MAILED: 09/18/2002

10

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application N .

09/674,913

Applicant(s)

GAUDERNACK ET AL.

Examiner

Christopher Nichols, Ph.D.

Art Unit

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 03 July 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 27-57 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 27-57 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: |

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 27-37 drawn to a peptide and pharmaceutical compositions comprising the same, classified in class 514, subclass 2, for example.
 - II. Claim 38 drawn to a vaccine for Alzheimer's disease comprising a peptide and pharmaceutical compositions comprising the same, classified in class 424, subclass 184.1.
 - III. Claims 39-43 drawn to a method for vaccinating a human patient, classified in class 424, subclass 184.1.
 - IV. Claims 44-47, drawn to a method for treating a human patient comprising stimulating the patient in *in vivo* or *ex vivo* with at least one peptide, classified in class 514, subclass 2, for example.
 - V. Claims 48-49 and 52-55, drawn to an isolated DNA sequence and vectors comprising the same, classified in class 435, subclass 320.1, for example.
 - VI. Claims 50-51, drawn to a method for treating a human patient comprising stimulating the patient *in vivo* or *ex vivo* with a DNA sequence, classified in class 514, subclass 44, for example.
 - VII. Claims 56 and 57, drawn to a method for treating a human patient comprising stimulating the patient *in vivo* or *ex vivo* using a vector, classified in class 435, subclass 320.1, for example.

Art Unit: 1647

2. The inventions are distinct, each from the other because of the following reasons:

3. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to different methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Inventions III, IV, VI, and VII are directed to methods that are distinct both physically and functionally, and are not required one for the other. Invention III requires search and consideration of a method of vaccinating a human patient, which is not required by any of the other Inventions. Invention IV requires search and consideration of stimulating a patient *in vivo* or *ex vivo* with at least one peptide, which is not required by any of the other Inventions. Invention VI requires search and consideration of stimulating a patient *in vivo* or *ex vivo* with a DNA sequence, which is not required by any of the other Inventions. Invention VII requires search and consideration of stimulating a patient *in vivo* or *ex vivo* using a vector, which is not required by any of the other Inventions.

4. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different products, restriction is deemed to be proper because these products constitute patentably distinct inventions for the following reasons. Inventions I, II, and V are directed to products that are distinct both physically and functionally, are not required one for the other, and are therefore patentably distinct. The peptide of Invention I can be prepared by processes which are materially different from DNA of Invention V, such as by chemical synthesis, or by isolation and purification from natural sources. Further, the peptide of Invention I can be used in materially different methods other than to make the vaccine of Invention II, such as in diagnostic methods (e.g., in screening). The vaccine

Art Unit: 1647

composition of Invention II requires the peptide of Invention I, however, the vaccine compositions can be used in compositions and methods unrelated to therapy, such as making antibodies *in vitro*. The peptide components of Invention II can be prepared by processes which are materially different from DNA of Invention V, such as by chemical synthesis, or by isolation and purification from natural sources. The DNA of Invention V is independent and distinct from the product of Invention II because it is not required to make the DNA of Invention V. Although the DNA of Invention V can be used to obtain the peptide of Invention I it can also be used in materially different methods, such as in various diagnostic (e.g., *in situ* hybridizations), or therapeutic methods.

5. Inventions I and each of III and IV are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the processes for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different process of using that product. The peptide of Invention I can be used to isolate receptors.

6. Inventions II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different

Art Unit: 1647

process of using that product. The vaccine of Invention II can be used to produce antibodies *in vitro*.

7. Inventions V and each of VI and VII are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the processes for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different process of using that product. The DNA of Invention V can be used to express the peptide of Invention I.

8. Inventions I and each of VI and VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions I and each of VI and VII are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions VI and VII do not recite the use or production of the peptides of Invention I.

9. Inventions II and each of IV, VI, and VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions II and each of IV, VI, and VII are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions IV, VI, and VII do not recite the use or production of the vaccine of Invention II.

Art Unit: 1647

10. Inventions V and each of III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions V and each of III and IV are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions III and IV do not recite the use or production of the DNA sequence and vectors of Invention V.

11. **FURTHERMORE, restriction to one of the following inventions is required under 35 U.S.C. 121:**

- A. Claims 27-57, each in part, as the inventions pertain to SEQ ID NO: 1.
- B. Claims 27-57, each in part, as the inventions pertain to SEQ ID NO: 2.
- C. Claims 27-57, each in part, as the inventions pertain to SEQ ID NO: 3.
- D. Claims 27-57, each in part, as the inventions pertain to SEQ ID NO: 4.
- E. Claims 27-57, each in part, as the inventions pertain to SEQ ID NO: 5.
- F. Claims 27-57, each in part, as the inventions pertain to SEQ ID NO: 6.
- G. Claims 27-57, each in part, as the inventions pertain to SEQ ID NO: 7.
- H. Claims 27-57, each in part, as the inventions pertain to SEQ ID NO: 8.
- J. Claims 27-57, each in part, as the inventions pertain to SEQ ID NO: 9.
- K. Claims 27-57, each in part, as the inventions pertain to SEQ ID NO: 10.

12. The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1647

13. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to different sequences, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Inventions A, B, C, D, E, F, G, H, J, and K are directed to sequences that are distinct both physically and functionally, and are not required one for the other.

Invention A requires search and consideration of SEQ ID NO: 1, which is not required by any of the other Inventions. Invention B requires search and consideration of SEQ ID NO: 2, which is not required by any of the other Inventions. Invention C requires search and consideration of SEQ ID NO: 3, which is not required by any of the other Inventions. Invention D requires search and consideration of SEQ ID NO: 4, which is not required by any of the other Inventions.

Invention E requires search and consideration of SEQ ID NO: 5, which is not required by any of the other Inventions. Invention F requires search and consideration of SEQ ID NO: 6, which is not required by any of the other Inventions. Invention G requires search and consideration of SEQ ID NO: 7, which is not required by any of the other Inventions. Invention H requires search and consideration of SEQ ID NO: 8, which is not required by any of the other Inventions.

Invention J requires search and consideration of SEQ ID NO: 9, which is not required by any of the other Inventions. Invention K requires search and consideration of SEQ ID NO: 10, which is not required by any of the other Inventions.

14. Applicant is advised that this is not a requirement to elect a species. Rather, this is a second restriction requirement superimposed upon the requirement to elect one group from I-VII. In order to be fully responsive, Applicant must elect one group from I-VII and one group from A-H, J-K.

Art Unit: 1647

15. This application contains claims directed to the following patentably distinct species of the claimed invention:

- a. Alzheimer's disease
- b. Down's syndrome

16. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 39-47, 50-51, and 56-57 are generic.

17. If applicant selects any one of Inventions III, IV, VI, or VII one species from the disease group must be chosen to be fully responsive.

18. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

19. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

20. This application contains claims directed to the following patentably distinct species of the claimed invention:

- c. Mutant β APP protein
- d. Mutant Ubi-B protein

Art Unit: 1647

21. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 27-37 are generic.

22. If applicant selects Invention III, one species from the protein group must be chosen to be fully responsive.

23. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

24. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

25. This application contains claims directed to the following patentably distinct species of the claimed invention:

- e. Orthopox virus
- f. Canary virus
- g. Capripox virus
- h. Suipox virus
- i. Vaccinia virus
- j. Baculovirus

- k. Human adenovirus
- l. SV40 virus
- m. Bovine papilloma virus

26. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 19 and 20 are generic.

27. If applicant selects Invention V, one species from the recombinant viral vector group must be chosen to be fully responsive.

28. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

29. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

30. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and/or different classification, restriction for examination purposes as indicated is proper.

Art Unit: 1647

31. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

32. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1647

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher Nichols, Ph.D. whose telephone number is 703-305-3955. The examiner can normally be reached on Monday through Friday, 8:30AM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, Ph.D. can be reached on 703-308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications. The fax phone numbers for the customer service center is 703-872-9305.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

CJN
September 12, 2002

Gary D. Kunz